A patient with relapsing MOG antibody-associated disease continues to relapse on mycophenolate. The neuroimmunology team elects to use maintenance

Question

A patient with relapsing MOG antibody-associated disease continues to relapse on mycophenolate. The neuroimmunology team elects to use maintenance intravenous immunoglobulin. Which regimen is most appropriate?

Accepted Answer

1–2 g/kg over 2–5 days, followed by regular maintenance infusions every 4–6 weeks

Answer

1 g/kg daily for 14 days, followed by a fixed annual maintenance dose

Answer

2 g/kg every week until the serum MOG-IgG assay becomes negative

Answer

0.4 g/kg once, then no further treatment unless another relapse occurs

Answer

0.1 g/kg every six months, titrated only against serum immunoglobulin concentration

MOGAD – Maintenance IVIg — SCE Neurology MCQ

A patient with relapsing MOG antibody-associated disease continues to relapse on mycophenolate. The neuroimmunology team elects to use maintenance intravenous immunoglobulin. Which regimen is most appropriate?